AT403713T - Stamzellfaktor - Google Patents

Stamzellfaktor

Info

Publication number
AT403713T
AT403713T AT99122861T AT99122861T AT403713T AT 403713 T AT403713 T AT 403713T AT 99122861 T AT99122861 T AT 99122861T AT 99122861 T AT99122861 T AT 99122861T AT 403713 T AT403713 T AT 403713T
Authority
AT
Austria
Prior art keywords
stamzellfaktor
Prior art date
Application number
AT99122861T
Other languages
German (de)
Inventor
Krisztina M Zsebo
Sidney Vaughn Suggs
Robert A Bosselmann
Francis Hall Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US42238389A priority Critical
Priority to US53719890A priority
Priority to US57361690A priority
Priority to PCT/US1990/005548 priority patent/WO1991005795A1/en
Priority to US58970190A priority
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AT403713T publication Critical patent/AT403713T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/409Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
AT99122861T 1989-10-16 1990-10-04 Stamzellfaktor AT403713T (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US42238389A true 1989-10-16 1989-10-16
US53719890A true 1990-06-11 1990-06-11
US57361690A true 1990-08-24 1990-08-24
PCT/US1990/005548 WO1991005795A1 (en) 1989-10-16 1990-09-28 Stem cell factor
US58970190A true 1990-10-01 1990-10-01

Publications (1)

Publication Number Publication Date
AT403713T true AT403713T (en) 2008-08-15

Family

ID=27503703

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99122861T AT403713T (en) 1989-10-16 1990-10-04 Stamzellfaktor
AT90310899T AT194651T (en) 1989-10-16 1990-10-04 stem cell factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT90310899T AT194651T (en) 1989-10-16 1990-10-04 stem cell factor

Country Status (11)

Country Link
US (3) US6218148B1 (en)
EP (4) EP0676470A1 (en)
CN (2) CN1289526C (en)
AT (2) AT403713T (en)
CZ (3) CZ286304B6 (en)
DE (3) DE69033584D1 (en)
DK (1) DK0423980T3 (en)
GR (1) GR3034559T3 (en)
HK (1) HK1010397A1 (en)
SG (2) SG43009A1 (en)
SK (2) SK98199A3 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759215B1 (en) * 1989-10-16 2004-07-06 Amgen Inc. Method of preparing human stem cell factor polypeptide
EP0536317A1 (en) * 1990-06-25 1993-04-14 Immunex Corporation Mast cell growth factor
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US20050276784A1 (en) * 1990-08-27 2005-12-15 Solan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
US5767074A (en) * 1990-08-27 1998-06-16 Sloan-Kettering Institute For Cancer Research Compositions of soluble C-kit ligand and hematopoietic factors
DE4224050A1 (en) * 1991-07-31 1993-02-04 Hoffmann La Roche Soluble kit ligand
HU219540B (en) * 1992-04-23 2001-05-28 Sloan-Kettering Institute For Cancer Research Ligand for the c-kit receptor and methods of use thereof
US6001803A (en) * 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5525708A (en) * 1994-03-28 1996-06-11 Cytomed, Inc. Covalent dimer of kit ligand
EP0789761B1 (en) * 1994-11-04 2005-07-20 Applied Research Systems ARS Holding N.V. Human scf, a splice variant thereof, its pharmaceutical use
US5824789A (en) * 1995-06-07 1998-10-20 Systemix, Inc. Human growth factors, nucleotide sequence encoding growth factors, and method of use thereof
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
RO120579B1 (en) 1995-10-04 2006-04-28 Immunex Corporation Use of flt3-ligand
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
EP0953354A4 (en) * 1996-08-13 2002-10-23 Fujisawa Pharmaceutical Co Hematopoietic stem cell proliferating agents
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5969105A (en) * 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
JPH10158188A (en) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd Composition for treating cornea
AT480558T (en) * 1999-12-23 2010-09-15 Univ Geneve inhibitors on scf peptide-based basolateral sorting signal and for that
EP1315672A4 (en) 2000-06-22 2006-04-26 Rxkinetix Inc Delivery vehicle composition and methods for delivering antigens and other drugs
US6875441B2 (en) * 2000-06-26 2005-04-05 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
EP1406680A4 (en) * 2001-06-15 2007-01-10 Johns Hopkins Singapore Pte Lt Biofunctional fibers
AU2002363322A1 (en) * 2001-10-26 2003-05-19 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
CN100422334C (en) * 2001-11-27 2008-10-01 内克西特股份有限公司 Production of eukaryotic proteins and nucleic acid molecules in c. elegans
US7994125B2 (en) 2003-02-14 2011-08-09 Istituto Superiore Di Sanita Stem cell factor for preventing chemotherapy-induced depletion of blood cells
US7999071B2 (en) 2003-12-12 2011-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
WO2006002344A1 (en) * 2004-06-23 2006-01-05 Epigenomics Ag Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders
CN1993460A (en) * 2004-07-12 2007-07-04 索林集团意大利有限公司 Device and method for cultivating human cell
WO2006055260A2 (en) * 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
JP2008543839A (en) 2005-06-14 2008-12-04 アムジェン インコーポレーテッドAmgen Inc. Self-buffering protein formulations
WO2007037795A2 (en) * 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
AU2006315601A1 (en) * 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
WO2007102814A2 (en) * 2006-03-07 2007-09-13 Regenetech, Inc. Recombinant mammalian molecules and method for production thereof
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
AU2007230902B2 (en) 2006-03-24 2013-03-14 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
EP2679221A1 (en) * 2006-10-20 2014-01-01 Children's Medical Center Corporation Method to enhance tissue regeneration
US20110206781A1 (en) * 2008-05-28 2011-08-25 Zon Leonard I Method to modulate hematopoietic stem cell growth
CN102307989B (en) 2008-11-14 2015-04-22 生物载体株式会社 Method for producing dendritic cells
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2012096960A2 (en) * 2011-01-10 2012-07-19 The Regents Of The University Of Michigan Stem cell factor inhibitor
EP2785834A4 (en) 2011-12-02 2015-04-29 Fate Therapeutics Inc Enhanced stem cell composition
JP6106688B2 (en) 2011-12-02 2017-04-05 フェイト セラピューティクス,インコーポレイテッド An improved method of treating ischemia
LT6161B (en) 2013-09-27 2015-06-25 Uab Profarma Fused proteins of granulocyte colony-stimulating factor with other partners of growh factor, preferably with stem cell factor, and method of preparation thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105985424A (en) * 2015-01-30 2016-10-05 苏州方舟基因药业有限公司 Stem cell factor functional peptide fragment and application thereof
CN105749252A (en) * 2016-04-29 2016-07-13 南方医科大学 Application of IL-9 serving as medicine for treating thrombocytopenia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695542A (en) * 1983-10-04 1987-09-22 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS62223126A (en) 1986-03-25 1987-10-01 Sankyo Co Ltd Growth factor for blood stem cell
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1

Also Published As

Publication number Publication date
CZ9700490A3 (en) 2000-01-12
CN1051937A (en) 1991-06-05
SK500890A3 (en) 2001-04-09
AT194651T (en) 2000-07-15
CZ9700491A3 (en) 2000-01-12
DE69034258D1 (en) 2008-09-18
CZ286305B6 (en) 2000-03-15
DK0423980T3 (en) 2000-10-09
CN1306007A (en) 2001-08-01
US6207802B1 (en) 2001-03-27
EP0423980A1 (en) 1991-04-24
CN1075078C (en) 2001-11-21
CZ286303B6 (en) 2000-03-15
EP1241258A3 (en) 2003-12-10
US6218148B1 (en) 2001-04-17
SK98199A3 (en) 2001-04-09
SK281487B6 (en) 2001-04-09
CZ286304B6 (en) 2000-03-15
SG59931A1 (en) 1999-02-22
EP0423980B1 (en) 2000-07-12
US6207417B1 (en) 2001-03-27
SK281484B6 (en) 2001-04-09
DE69033584D1 (en) 2000-08-17
DE69033584T2 (en) 2001-03-08
EP0992579B1 (en) 2008-08-06
EP1241258A2 (en) 2002-09-18
CN1289526C (en) 2006-12-13
CZ9700488A3 (en) 2000-01-12
EP0992579A1 (en) 2000-04-12
EP0676470A1 (en) 1995-10-11
HK1010397A1 (en) 2000-12-29
GR3034559T3 (en) 2001-01-31
SG43009A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
DE69028564T2 (en) resistant Perfluoropolyätheremulsionen
AT158659T (en) Confokales scan-endoscope
TR24579A (en) Pestisidalû3-cyano-5-alkoxy-1-arylpyrazoles
FI98573B (en) Läheisyysdetektori
FI98357B (en) Pakkaussovitelma
FI102082B1 (en) Jäähdytysnestekoostumuksia
FI920471A0 (en) Kaareutusmekanismi
FI923770A (en) Dubbelriktad selectively avtryckbar taendare
NO920253A (en) Stroemningskondisjoneringsanordning
NO304700B1 (en) Tekstilmykningsmiddelblanding
NO173900C (en) Fluidstroemningsmaaler
NO922366D0 (en) Glyfosatsyreformulering
DE69032621D1 (en) Zweiwellenlängenlaserabtastmikroskop
DE69031750D1 (en) Osteoprotheseimplantat
DE69029869T2 (en) Epiduralsauerstoffsensor
DE19675051I2 (en) Aminosaeurederivate
DE69131866T2 (en) Spreizspektrumkorrelator
DE69025197T2 (en) Fötalsonde
DE69033469T2 (en) Imidazoalkensäure
DE69029542D1 (en) Viterbidekodierer
DE69034258D1 (en) Stamzellfaktor
NO180214B (en) Brönnsonde
DE69031367T2 (en) Blockübertragungs- and Koprozessorschnittstellenbefehl
DE69033697D1 (en) Mykonematizide
DE69033803D1 (en) Positionsauswerteschaltung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties